Patient Derived Xenograft (PDX) models are innovative tools used in preclinical oncology research and drug development which helps replicate the complexity and heterogeneity of human cancers. PDX models are developed by directly transplanting fresh tumor tissues resected from cancer patients into immunodeficient mice. This allows the tumors to grow and maintain their original complexity, heterogeneity, and molecular and cellular composition found in patients’ original tumor. PDX models closely mimic human cancers biologically, architecturally, and genetically and helps understand cancer development, progression, and response to different therapies. They provide crucial information about which cancer drug or treatment regimen would likely be effective for a specific patient. The increasing focus on personalized and precision medicine, to match the right treatment to the right patient, is a major driver.

The global Patient Derived Xenograft Model Market is estimated to be valued at Us$ 39.7 Million In 2024 and is expected to exhibit a CAGR Of 4.0% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

One of the key trends in the patient derived xenograft model market is growing popularity and acceptance of PDX models among pharmaceutical companies for preclinical drug development and efficacy testing. PDX models better predict clinical outcomes of cancer therapeutics compared to standard cell line models. They recreate the tumor heterogeneity and microenvironment present in actual cancer patients. Major pharmaceutical companies are increasingly relying on PDX models over past few years to accelerate drug discovery and development process. For example, Roche has developed a PDX biobank with over 2,500 models to test new oncology drugs and Chugai Pharmaceutical entered into strategic collaboration with Crown Bioscience to utilize their PDX platform for oncology drug development.

Porter’s Analysis

Threat of new entrants: Low due to high capital requirements and established intellectual property of existing players.

Bargaining power of buyers: Moderate bargaining power due to availability of substitutes. However, personalized therapies provide unique value.

Bargaining power of suppliers: Low as supply chains are global and suppliers do not have pricing leverage over manufacturers.

Threat of new substitutes: High threat from alternative therapeutic approaches like organoids and cell lines that provide personalized efficacy data.

Competitive rivalry: Intense competition among existing players to improve efficacy and clinical relevance of models.

Key Takeaways

The Global Patient Derived Xenograft Model Market Demand is expected to witness high growth. The global Patient Derived Xenograft Model Market is estimated to be valued at US$ 39.7 million in 2024 and is expected to exhibit a CAGR of 4.0% over the forecast period 2024 to 2031.

Regional analysis comprises Asia Pacific region is expected to emerge as the fastest growing market due to increasing R&D activities and demand for personalized therapies.

Key players operating in the patient derived xenograft model market are Crown Bioscience Inc., WuXi AppTec, Champions Oncology, Inc., The Jackson Laboratory, ONCODESIGN, Charles River Laboratories International, Inc., EPO Berlin-Buch GmBH, Shanghai LIDE Biotech Co., Ltd, Xentech.

Huge investments in R&D activities for cancer research from both private and public sectors are supporting market growth. Patient derived xenograft models are increasingly replacing traditional xenotransplantation approaches owing to their ability to retain key characteristics of original patient tumors. Growing demand for personalized medicine is also augmenting market expansion.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it